Since 2017, Cell & Gene Therapy World Asia has witnessed huge success in bringing over 300 industry pioneers from both cell & gene therapy industry. With the mission to facilitate the research & development and manufacturing of high quality cell & gene therapy treatments and regenerative medicines in Asia, Cell & Gene Therapy World Asia is going to continue its legacy.
In addition, this year, speakers will be exploring innovations in cell & gene therapy in Asia region, best practices on cell & gene therapy manufacturing and process development, scale out strategies, cost optimization, next generation on CART, advances in CART manufacturing, preparation for commercialization, regulation case studies and more.
Join the conference to interact with key and upcoming entities from Asia cell & gene therapy companies including BeiGene, Gracell Biotechnologies, Fosun Kite Biotechnology, Tessa Therapeutics, CARSgen, Senlang Bio, Kangstem Biotech, Medigen Biotechnology Corp, Shangai UniCAR Therapy among others.
Catch the latest cell & gene therapy development in Asia. From current best R&D practices to advancing towards manufacturing and commercialization from most-exclusive case studies to industry's key needs. All this and more under 1 roof.
Innovations & Opportunities in Cell & Gene Therapy in APAC Region
Upstream & Downstream Processing
Lentiviral Vectors for T cell Engineering
Characterization and Analysis of Cell Therapy
Vector Engineering , Design & Production
Viral Vector Downstream Process
Viral Vector Characterisation & Biosafety Testing
Advancing Gene Therapy to the Clinic
De-Risking the Supply Chain Logistics and Delivery
Preparing For Commercialization And Launch Strategy Success
Antonio Lee serves as the CEO and Managing Director at MEDIPOST America Inc., a wholly-owned U.S. subsidiary of MEDIPOST. He is also the Global Head of business development at Medipost , S.Korea.Prior to this he was the Chairman, Board of DirectorsatShandong Orlife Pharmaceutical Co.,China and is also Chairman, Board of Directors at EVASTEM Co., Ltd. Tokyo, Japan
Since 2011, Dr. Lee has been involved in the global commercialization and clinical development strategy, regulatory affairs and marketing of human Umbilical Cord Blood (hUCB)-derived Stem Cell technology and products developed by MEDIPOST, including the World’s First regulatory-approved allogeneic stem cell product - CARTISTEM®, for the treatment of knee Osteoarthritis (OA).
He is a Doctor of Philosophy, University of Otago, Dunedin, New Zealand Developmental Biology & Embryology ; A Master of Science,University of Otago, Dunedin, New Zealand Clinical Anatomy and Bachelor of Science with Honours, University of Otago, Dunedin, New Zealand Anatomy & Physiology
He has published several articles in world renowed journals on various topics around stemcells and regenerative medicine.
Dr. Kuan co-founded ARCE Therapeutics in 2020 and is the President and CEO. He leads ARCE from discovery toward clinical trials in developing next generation cell therapies such as CAR-engineered cells, for cancer treatment, including liquid and solid tumors, and immunological disorder diseases. He has more than 30 years of experience in research and development of therapeutic antibodies, protein fusions, and cellular gene therapy for the treatment of cancer, autoimmune, neurodegenerative and infectious diseases, including Duke University Medical Center and Development Center for Biotechnology. His areas of expertise include antibody engineering, recombinant immunotoxins, bispecific antibodies, and CAR-T/NK cell therapies for cancer treatment. Dr. Kuan obtained his Ph.D. degree from Purdue University in the USA; and his B.S. degree from National Taiwan University in Taiwan.
Assistant Professor Francesca Lim is a Consultant Haematologist at Singapore General Hospital (SGH), Deputy Head, Principal Lead (Education) and Lead (Blood Cancers) at the SingHealth Duke-NUS Cell Therapy Centre and Assistant Medical Director at the Cell Therapy Facility, Health Science Authority.
She spent two years training at the MD Anderson Cancer Center in CAR T-cell therapy, particularly in CAR-NK cell therapy. She has been instrumental in supporting and coordinating the Cell Therapy Programme at the SGH Department of Haematology, both at the clinical and research levels.
Ivan D Horak
Dr. Horak brings more than 20 years of experience in the global pharmaceutical industry, predominantly focused on oncology drug development, and is a board-certified medical oncologist. Prior to joining Tessa, Dr. Horak was Head of Global R&D and Chief Scientific and Medical Officer at Symphogen, a clinical-stage antibody company, and President of R&D at Enzon Pharmaceuticals, Inc. Dr. Horak has also held a number of senior research leadership positions in various pharmaceutical companies as well as at the National Cancer Institute (NCI). During his career, Dr. Horak has advanced multiple oncology treatments into the clinic, and has successfully led a number of FDA new drug applications.
Keiichi Fukuda is pioneer of the cardiac regeneration field and has been at its cutting edge for the past 20 years. He has made several contributions to both the fundamental biology of the stem cells and how to regenerate cardiomyocytes and to transplant them into the in vivo heart. He first reported that bone marrow mesenchymal stem cells can be induced to differentiate into cardiomyocytes in vitro. He first developed a method to generate iPS cells from peripheral circulating T lymphocytes using Sendai virus containing Yamanaka factors. He found several factors such as noggin, Wnt and G-CSF, and applied them to induce cardiomyocytes. He also developed novel method to purify the cardiomyocytes by the difference of metabolic energy pathway. He became Chief Professor of the Department of Cardiology in Keio University, and published more than 600 top-ranked papers including Nature- and Cell-sister journals. He served as an associate editor of JMCC and JCF, and a consulting editor of Circulation Research. He also worked as editorial board members for more than 10 international journals. He had established bio-venture company “Heartseed Inc.” in 2015 and became CEO. He is now planning to examine the clinical trial for transplantation of human iPS-derived regenerated cardiomyocytes to the patients with congestive heart failure in 2022.
William Hung, Ph.D.
Dr. Yu Zhang
Dr. Bin Xiang, a biologist by training, has solid research experience in disease biology, intestine biology, genome editing, AAV and bacterial vector gene therapy. Dr. Xiang founded CommBio Therapeutics Co., Ltd. in 2019 and devote to develop novel medicine by focusing on intestine biology and bacterial delivery system. Currently, Dr. Xiang is the CEO of CommBio, and the College Advisor at ShanghaiTech University.
Dr. Xiang obtained Ph.D in neurobiology from Fudan University Shanghai Medical School in 2001, followed by postdoctoral training in cancer biology at Cold Spring Harbor Laboratory and research fellow in cancer translational research at Vanderbilt University Medical Center.
In 2008, Dr. Xiang switched career to drug discovery and joined AstraZeneca Innovation Center China working on oncology translational medicine. In 2011, Dr. Xiang joined China Novartis Institutes for Biomedical Research. At Novartis, Dr. Xiang was the project team leader having directed both small molecular drug and AAV gene therapy in oncology and metabolic disease. In addition, Dr. Xiang led an innovation group exploring novel disease mechanism from intestine biology and developing new class of drug approaches including genome editing and gene therapy.
Dr. Bose Kalampanayil is Chief Technology Officer at Neurophth since 2019.Dr. Kalampanayil has over 20 years of experience in the biopharmaceutical industry, including CMC experience in cell and gene therapy and vaccine manufacturing. Most recent cell/gene therapy experience and consultations include, GMP Plasmid Productions, GMP Upstream and Downstream Productions for various AAVs (AAV2, 5, 6, 8 & 9). Served as a “Subject Matter Expert” in process engineering, process development and CDMO selection processes for GMP Manufacturing. Held management positions in several biotechnology companies and CDMOs in USA, including Vigene Biosciences, Therabron Therapeutics, AERAS, Iomai (Intercell) and Charles River Laboratories. Dr. Kalampanayil has a PhD in Biochemistry from University of Maryland and hold American Board certification in Clinical Chemistry.
John Rasko AO
Jose Carlos Segovia
Joyce CY Teng
Dr Qlintang joined KALBE in 1999 and now leads in three of Kalbe's subsidiaries, namely Stem Cell and Cancer Institute, is a Kalbe’s Research, PharmaMetric Labs, is a CRO company and Bifarma Adiluhung, is a Stem Cell Manufacture with GMP certificate.
He is a reviewer member in Ministry of Research and Technology/National Research and Innovation Agency (Indonesia)since2019 and also member in Consortium of tissue engineering and stem cells, Ministry of Health since 2014, board member in Association of Indonesia Tissue Engineering and Cell Therapy since 2016 and member of Association of Indonesia’s Stem Cells since 2020.
Yann Chong Tan
Sartorius Stedim Biotech is a leading partner of the biopharma industry. Our solutions support our customers in producing drugs safely, timely and economically. The key product categories of our company are cell cultivation, fermentation, filtration, purification, and fluid management.
At Astrea Bioseparations every detail matters as we work to create tailored solutions that streamline bioprocesses from research through commercial phases. We actively support customers with products and services that enable them to bring next-generation therapies to the market to treat and cure diseases
Halo Labs knows aggregates and particles. The Aura can count and characterize subvisible particles and tell you if they are aggregated drug product, excipients, or external contaminants. A simple, plate-based approach enables low-volume, high-throughput, fully automated particle imaging and analysis at any stage from developability assessment through quality control.”
Peli BioThermal is the first cold chain packaging solutions provider to make available a broad and comprehensive portfolio of patented and award-winning single-use and reusable thermal protection packaging solutions for the safe transport of pharmaceuticals, clinical trials, diagnostics, tissue, vaccines and blood supplies for the life science industry.
Collaboration with our clients is the first step to ensure we provide a solution that is built around the unique and very specific needs of your temperature-sensitive payloads. Our global services network provides consultation, support, engineering and deployment for your cold chain distribution challenges wherever they exist.
Peli BioThermal designs products to ensure our customers valuable payloads are kept in perfect condition, irrespective of external temperatures and conditions. They are designed to be strong and robust, to survive the rigors of international transport. With environmental issues in mind, we ensure that our design team specify the correct materials and consider ‘end of life’ recycling for all of our ranges, whether they are single use or reusable packaging systems.
Eppendorf – Stimulating growth. Cultivating Solutions
Efficient bioprocesses are central to the production of biopharmaceuticals, biomass, chemical building blocks, and nutritional products. Scientists from industry and academia trust Eppendorf bioprocess solutions for the cultivation of mammalian, insect, plant, and stem cells, as well as bacteria, yeasts, and fungi. Scalable systems support the upstream bioprocessing cycle from early development to scale-up to pilot-scale production, in working volumes from 65 mL to 2,400 L. Powerful hardware and software tools for process monitoring, control, and analytics, help to build process understanding and facilitate standardized process control. By utilizing the strong synergies between bioreactor technology and polymer manufacturing, Eppendorf developed a wide selection of single-use bioreactors and fermentors which complement its portfolio of glass and stainless-steel vessels. With worldwide technical and application services, clear technical documentation, and preventive maintenance services, Eppendorf ensures reliable system operation.
Since 1945, the Eppendorf brand has been synonymous with customer-oriented processes and innovative products, such as laboratory devices and consumables for liquid handling, cell handling and sample handling. Today, Eppendorf and its more than 5000 employees serve as experts and advisors, using their unique knowledge and experience to support laboratories and research institutions around the world.
Marken is a wholly owned subsidiary of UPS and is the essential clinical part of UPS Healthcare. With Marken, BOMI Group and Polar Speed included, the UPS Healthcare network staffs 199 locations with 10,000+ employees worldwide. Marken offers a state-of-the-art GMP-compliant depot network and logistic hubs for clinical drug product storage and distribution in 59 locations worldwide, while maintaining the leading position for Direct-to-Patient and Home Healthcare services, biological sample shipments and biological kit production. Marken’s dedicated 2,400+ staff members manage 154,000 drug product and biological sample shipments every month at all temperature ranges in more than 220 countries and territories and have orchestrated 14,000+ home healthcare visits. Additional services such as cell and gene supply chain services, ancillary material sourcing, storage and distribution, shipment lane verification and qualifications, as well as GDP, regulatory and compliance consultancy add to Marken’s unique position in the pharma and logistics industry.
Link to your website - https://www.marken.com/
Terumo Pharmaceutical Solutions develops patient-oriented parenteral delivery solutions for therapeutic performance and safety Globally trusted for quality and precision, Terumo Pharmaceutical Solutions offers pharmaceutical and medical device manufacturers around the world comprehensive product design and development services, for primary container, injection, infusion therapy devices, and contract development and manufacturing services (CDMO).
We have decades of experience collaborating with pharmaceutical companies from the earliest phases of drug development to product commercialization to optimize critical aspects of parenteral
drug delivery. Innovation and creativity are central to our value proposition. Our expert teams lead the industry in developing and manufacturing advanced, high-performing infusion and injection technologies for
all parenteral applications. We provide sterile injectable contract development and manufacturing (CDMO) services from initial combination device design and formulation development to commercial manufacturing.
supporting better patient outcomes around the world.
We listen. We question. We deliver.
Tofflon Science and Technology Group Co. Ltd. was established in 1993 and is a one-stop solution provider for bio/pharmaceutical industry. Besides being a comprehensive pharmaceutical equipment supplier, Tofflon also provides process support, core equipment, integrated systems, pharma engineering (Modular construction & Site build construction) and consumables such as media, resin and single use systems for the pharma and biotech industry around the world.
Since founded, Tofflon has supplied and supported more than 12,000 sets of equipment and systems for 3,000 pharmaceutical companies across over 50 countries and regions in the world which have been widely applied in the fields of R&D, liquid and lyo injectables, chemical API, bioengineering and pharma packaging. Tofflon has also been approved with all the international regulatory certifications like German TUV ISO9001, ISO14001, OHSAS 18001, CE, UL, ASME, PED, etc.Today, Tofflon Science and Technology Group Co. Ltd has over 5500 employees around the globe with a total asset of over 2 billion USD. The company currently has several R&D centres around the world (China, Italy and Germany) and is expanding further. Through our Technological Innovation and Development Concept: Automation, Intelligence, Modularization, Continuous Processing and System Integration, we create values for the industry and our partners: cGMP compliance, High Efficiency, Automation, Simple Interface, Cost Effective, Easy Validation, Integrated Service, and Faster Time to Market.
For 42 years, QuickSTAT has been providing the leading pharma and biotech companies 24/7/365 global life science logistics solutions from R&D, clinical trials through to commercialization.
Our logistics experts provide time-and temperature-sensitive transport of clinical research samples, cell and gene therapies, investigational drugs, clinical trial supplies and vaccines, to bring new drugs to market.Strict chain of custody, chain of identity and GDP protocols ensure product integrity and patient safety for all clinical and commercial personalized medicines QuickSTAT transports. Consultation and procurement of proper packaging—from controlled room temperature to cryofrozen. Next gen IT logistics software provided for managing your clinical supply chain with real-time temperature and tracking technology.
Malaysia Association for Cell Therapy (MACT) was established on the 15th February 2012 to provide support to Malaysia's cell therapy industry and research. MACT's full membership comprises various industry players including:
- Cell therapy technology providers (eg various university and commercial labs)
- Cell therapy healthcare providers (eg various hospitals and clinics providing such treatment)
- And various suppliers of goods and services to the industry such as lab operators, cell production and banking facility, product testing/QC labs, CROs, consultants etc.
MACT also represent and work with the relevant regulatory authorities or agency responsible for cell therapy product approvals to ensure that sufficient data and assessments are available for the industry development and oversight for the industry development and oversight
MACT formation was motivated by the increasing recognition of cell therapy as an important industry to our country. For more information, please visit www.mact.org.my
Biotech Connection Singapore (BCS) is a non-profit organisation that aims to promote and support entrepreneurship in life sciences, biotech, medtech and healthcare by forming a platform for academics, entrepreneurs, industry professionals as well as government agencies to interact and build connections.
For more information visit: https://www.
BioPharma Asia aims to keep its readers abreast of all developments in the areas of Manufacturing, Development, Quality Assurance, Outsourcing, and Regulatory Affairs, with only the highest quality articles and webinars written and presented by the most respected authors/presenters, associated with only end-user companies. This ensures that the information will always be guaranteed to remain timely, informative and above all totally unbiased.
Limited Special Price - END USER
- Main Conference Access
- Expires 30th June 2023
- Standard Rate SGD 2595
Limited Special Price - VENDOR/BD
- Main Conference Access
- Expires 30th June 2023
- Standard Rate SGD 4395
Cell & Gene Therapy growing fast in the Asia region with a lot of support seen from the regulatory and its advancement in research. Many of the Academic & Research Institutes have been contributing to the cell & gene space with great research, discovery and advances.
At the 7th Annual Cell & Gene Therapy World Asia, we will be featuring the top research work done by Academia. We've had overwhelmingly positive response from some of the key players in the Cell & Gene Manufacturing sector who are interested in the latest research work done by Academic and Research Institutes.
The poster presentation will be viewed by 300+ Cell & Gene industry professionals from top notch Cell & Gene Companies. Interested in giving a presentation? Enquire now...
Asia Pacific Cell & Gene Therapy Excellence Awards 2023
Asia Pacific CGT Excellence Awards 2023 seeks to give recognition to exceptional Cell & Gene Therapy Pioneers, Researchers, Innovators & Manufacturers that facilitate fast advancement in new therapies, R&D and manufacturing. Featuring top Cell & Gene Therapy leaders in the industry, along with the new cell & gene therapy research development, latest advances and technologies and best practices in Cell & Gene manufacturing, the Asia Pacific CGT Excellence Awards 2023 applauds extraordinary leaders & trend-setters of today and inspires innovators of tomorrow.
Present your expertise to the key cell and gene therapy stakeholders from Asia through a variety of available speaking packages.
Join the exhibition, and build an impressive presence among your potential clients.
Emphasize on your messages by promoting your brand alongside exhibition and thought leadership.
Engage with and build lasting connections that matter the most to your business.
Gain exclusive access to contacts of high-profile attendees through intimate networking opportunities.